Novel PPFIA1-ALK, ALK-C2orf91(intergenic) double-fusion responded well to alectinib in an advanced lung adenocarcinoma patient: a case report

por Yan, Lingxin, Zheng, Jiayu, Pan, Qingyun, Liang, Yuxian, Yu, Pengli, Chen, Quanfang
Publicado 2023